Table 2.

Univariate and multivariate analysis of prognostic factors of cancer-specific survival using Cox regression model.

Factors	Univariate analysis		Multivariate analysis
	Hazard ratio (95% CI)	P value	Hazard ratio (95% CI)	P value
Age at prostate cancer diagnosis, years (≥ 70 vs. < 70)	0.673 (0.273–1.658)	0.3896
PSA at prostate diagnosis, ng/mL (< 100 vs. ≥ 100)	2.364 (0.695–8.045)	0.1684
Clinical stage (T3-4 vs. T1-2)	0.766 (0.315–1.860)	0.5556
TTCRPC, month (≥ 8 vs. < 8)	1.266 (0.509–3.148)	0.6118
TTCRPC, month (≥ 9 vs. < 9)	1.532 (0.648–3.621)	0.3312
Local therapy (yes or no)	1.467 (0.604–3.566)	0.5381
(Radical prostatectomy vs. radiation)	2.144 (0.679–6.767)	0.1936
Nadir PSA, ng/ml (≥ 0.2 vs. < 0.2)	1.236 (0.510–2.995)	0.6382
PSA reduction rate, % (< 99.5 vs. ≥ 99.5)	1.636 (0.631–4.241)	0.3107
TnPSA, months (≤ 12 vs. > 12)	1.768 (0.744–4.204)	0.1969
Age at CRPC diagnosis, years (≥ 75 vs. < 75)	0.689 (0.289–1.644)	0.4014
TTCRPC, month (≤ 24 vs. > 24)	2.292 (0.949–5.538)	0.0652
TTCRPC, month (≤ 12 vs. > 12)	5.692 (1.972–16.42)	0.0013*	3.714 (1.233–11.19)	0.0197*
PSA at CRPC diagnosis, ng/mL (≥ 10 vs. < 10)	0.755 (0.101–5.658)	0.7845
PSADT, month (≤ 3 vs. > 3)	3.738 (1.496–9.339)	0.0048*	3.005 (1.157–7.809)	0.0239*
Treatment groupa
DOC vs. ARAT	2.323 (0.800–6.757)	0.1212
Other therapiesb alone vs. DOC/ARAT	0.708 (0.259–1.937)	0.5017

CI confidence interval, PSA prostate-specific antigen, TnPSA time to nadir PSA from ADT initiation, CRPC castration-resistant prostate cancer, TTCRPC time to CRPC diagnosis from ADT initiation, ADT androgen deprivation therapy, PSADT PSA doubling time, DOC docetaxel, ARAT androgen receptor-axis targeted therapies.

*Statistically significant.

^aAll patients were treated by medical/surgical castration ^bOther therapies include flutamide, estramustine, and low-dose dexamethasone.